Christopher Burton, DO
Family Medicine · North Las Vegas, NVNPI 1700406675
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $369 and has fallen 92.8% since, to $27 in 2024.
Across 19 payments — averaging $37.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$156
- E.r. Squibb & Sons, L.L.C.$137
- Amgen$122
- Pfizer$122
- Merck$93
- Polynovo North America LLC$27
- plus $55 from 3 others
What the payments were for
- Food & beverage$711100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 5 | $156 |
| E.r. Squibb & Sons, L.L.C. | 2 | $137 |
| Amgen | 1 | $122 |
| Pfizer | 6 | $122 |
| Merck | 1 | $93 |
| Polynovo North America LLC | 1 | $27 |
| Gilead | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Exact Sciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$711 in reported general payments places this provider in the 65th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $388 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 44 | $243 |
| Doxycycline Monohydrate | 16 | $169 |
| Mupirocin | 20 | $148 |
| Cefdinir | 11 | $143 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $142 |
| Prednisone | 20 | $117 |
| Azithromycin | 23 | $77 |
| Amoxicillin | 23 | $61 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $32 |
Paid to pharmacies, not to this prescriber.
Other family medicine in North Las Vegas
- Naz WahabLas Vegas$563K
- Jerry CadeLas Vegas$180K
- Nilesh GokalLas Vegas$75K
- Bayo Curry-WinchellReno$74K
- Warren MagnusLas Vegas$70K
- Catherine McCarthyReno$68K
- Kimberly AdamsLas Vegas$51K
- Badi EghterafiHenderson$38K
- Francisco DofelizReno$30K
- Mandeep GillLas Vegas$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.